The stock is trading at $21.27 which is slightly above $18.53, the stock’s 50 day moving average and a tad above the 200 day moving average of $19.95. The 50 day moving average moved up $2.74 whereas the 200 day average was up by +6.63%. (NASDAQ:AIMT) shares saw light trading volume with 142K shares changing hands on Thursday. Overall, volume was down 61.21% under the stocks normal daily volume.
Traders are feeling more bearish on shares of Aimmune Therapeutics, Inc. of late as inferred by the change in short interest. The company realized a rise in short interest of 10.79% as of May 31, 2017 from the last reporting period. Short interest grew 459,986 over that timeframe. Days to cover increased 8.7 to 20.4 and the short interest percentage is 0.09% as of May 31.
Here is the rundown on market activity for Aimmune Therapeutics, Inc. (NASDAQ:AIMT). Warren L. Desouza, CFO disclosed the sale of 10,000 shares of (AIMT). The shares were purchased at an average price of $22.95. The CFO now owns $474,629 of the stock per the Form 4 SEC filing. Susan E. Barrowcliffe, General Manager, Europe disclosed the sale of 20,000 shares of AIMT stock. The shares were sold on November 11th for an average price of $25.00. Barrowcliffe now owns $0 of the stock according to the SEC filing.
See Remarks Mary M. Rozenman disclosed the sale of 24,096 shares. The shares were purchased at an average price of $17.60. The See Remarks now owns $0 of the stock according to the SEC filing.
Here are a few other firms who have also updated their positions. As of quarter end Next Financial Group, Inc had sold a total of 200 shares trimming its holdings by 33.3%. The value of the investment in AIMT went from $12,000 to $8,000 decreasing 33.3% quarter over quarter. As of the end of the quarter Daiwa Sb Investments Ltd. had disposed of 1,050 shares trimming its position 17.2%. The value of the total investment in Aimmune Therapeutics, Inc. decreased from $132,000 to $104,000 a change of 21.2% since the last quarter.
As of quarter end Morgan Stanley had bought a total of 8,013 shares growing its stake by 40.6%. The value of the investment in (AIMT) increased from $404,000 to $603,000 a change of $199,000 quarter to quarter. Goldman Sachs Group Inc augmented its position by buying 52,558 shares an increase of 124.5% as of 03/31/2017. Goldman Sachs Group Inc claims 94,774 shares with a value of $2,059,000. The total value of its holdings increased 138.6%.
On March 7 Credit Suisse kept the company rating at “Outperform” but lowered the price expectation from $44.00 to $35.00. On March 1 analysts at Wedbush started covering AIMT setting a rating of “Outperform” and setting a price target of $42.00.
January 22 investment analysts at Credit Suisse held the company rating at “Outperform” but raised the price target to $44.00 from $13.43. On August 31, 2015 Credit Suisse initiated coverage on the stock by announcing an initial rating of “Outperform” and establishing a price target of $44.00.
The company is so far trading up by 2.65 percent from yesterday’s close. In the last earnings report the EPS was $-2.03 and is expected to be $-2.66 for the current year with 50,342,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.71 with next year’s EPS projected to be $-3.27.
Aimmune Therapeutics, Inc., launched on June 24, 2011, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Business’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Business’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy..